STEVEN MEEKS: Open Payments
NPI 1003264300 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,081 in 149 payments from 22 companies in 2025. Trend: 2023 $396 · 2024 $2,888 · 2025 $3,081
Food & beverage: $2,866Education: $215
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation | 23 | $373 |
| ABBVIE INC. | 19 | $367 |
| GENZYME CORPORATION | 8 | $345 |
| UCB, Inc. | 12 | $310 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 10 | $280 |
| Novartis Pharmaceuticals Corporation | 18 | $269 |
| Janssen Biotech, Inc. | 14 | $227 |
| E.R. Squibb & Sons, L.L.C. | 10 | $170 |
| Lilly USA, LLC | 10 | $127 |
| Regeneron Healthcare Solutions, Inc. | 4 | $106 |
Products named: DUPIXENT, OPZELURA, Bimzelx, TREMFYA, COSENTYX, SKYRIZI, Sotyktu, ILUMYA.
Industry payments across CA — which companies pay providers there.
